Table 2.
Patients characteristics at baseline and at switching to second-line antiretroviral regimen
| Variable | At baseline |
At start of second-line regimen |
||||
|---|---|---|---|---|---|---|
| Routine viral load monitoring (n=6,369) | No routine viral load monitoring (n=13,744) | P value | Routine viral load monitoring (n=236) | No routine viral load monitoring (n=340) | P value | |
| Women (%) | 4,101 (64.4) | 8,350 (60.8) | <0.001 | 145 (61.4) | 181 (53.2) | 0.05 |
| Median age [IQR] (years) | 34 [30–41] | 35 [30–41] | <0.001 | 35 [31–41] | 38 [33–44] | <0.001 |
| Clinical stage (%) | <0.001 | |||||
| Stage available | 5,831 (91.6) | 11,588 (84.3) | 0 | 0 | ||
| Less advanced | 2,591 (44.4) | 3,343 (28.9) | ||||
| Advanced * | 3,240 (55.6) | 8,245 (71.2) | - | |||
| CD4 cell count (cells/μl) | <0.001 | |||||
| CD4 count available | 5,462 (85.8) | 10,315 (75.1) | 141 (59.7) | 261 (76.8) | ||
| Median [IQR] | 97 [42–163] | 129 [60–195] | 161 [77–265] | 102 [44–181] | ||
| HIV-1 viral load (copies/ml) | ||||||
| Viral load available (%) | 3,750 (58.9) | 271 (2.0) | 143 (60.6) | 14 (4.1) | ||
| < 10,000 (%) | 511 (13.6) | 71 (49.6%) | ||||
| 10,000–100,000 (%) | 1,455 (38.8) | 36 (25.2%) | ||||
| > 100,000 (%) | 1,784 (47.6) | 36 (25.2%) | ||||
| Median log viral load [IQR] | 5.0 [4.4–5.4] | 4.0 [3.4–5.0] | ||||
| First-line regimens (%) | <0.001 | |||||
| 3TC d4T EFV | 3,495 (54.9) | 9,717 (70.7) | ||||
| 3TC ZDV EFV | 1,193 (18.7) | 1,757 (12.8) | ||||
| 3TC d4T NVP | 1,050 (16.5) | 1,254 (9.1) | ||||
| 3TC ZDV NVP | 358 (5.6) | 955 (7.0) | ||||
| Other | 273 (4.3) | 61 (0.4) | ||||
| Second-line regimens (%) | <0.001 | |||||
| ZDV ddI LPV | 114 (48.3) | 58 (17.1) | ||||
| 3TC ddI IDV RTV | 0 (0) | 60 (17.7) | ||||
| ABC ddI LPV | 3 (1.3) | 43 (12.7) | ||||
| d4T ddI LPV | 19 (8.1) | 1 (0.3) | ||||
| 3TC ZDV LPV | 18 (7.6) | 18 (5.3) | ||||
| 3TC ZDV IDV RTV | 6 (2.5) | 28 (8.2) | ||||
| Other | 76 (32.2) | 132 (38.8) | ||||
IQR are shown in square brackets and percentages in brackets. ABC, abacavir; ddI, didanosine; EFV, efavirenz; d4T, stavudine; IQR, interquartile range; LPV, lopinavir; NVP, nevirapine; RTV: boost of ritonavir; 3TC, lamivudine; ZDV, zidovudine.
*
US Centers for Disease Control and Prevention (CDC) stage C, or World Health Organization (WHO) stages III or IV.